Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased cardiac fatty acid oxidation in a mouse model with decreased malonyl-CoA sensitivity of CPT1B.
van Weeghel M, Abdurrachim D, Nederlof R, Argmann CA, Houtkooper RH, Hagen J, Nabben M, Denis S, Ciapaite J, Kolwicz SC Jr, Lopaschuk GD, Auwerx J, Nicolay K, Des Rosiers C, Wanders RJ, Zuurbier CJ, Prompers JJ, Houten SM. van Weeghel M, et al. Among authors: zuurbier cj. Cardiovasc Res. 2018 Aug 1;114(10):1324-1334. doi: 10.1093/cvr/cvy089. Cardiovasc Res. 2018. PMID: 29635338
Canagliflozin inhibits inflammasome activation in diabetic endothelial cells - Revealing a novel calcium-dependent anti-inflammatory effect of canagliflozin on human diabetic endothelial cells.
Li X, Kerindongo RP, Preckel B, Kalina JO, Hollmann MW, Zuurbier CJ, Weber NC. Li X, et al. Among authors: zuurbier cj. Biomed Pharmacother. 2023 Mar;159:114228. doi: 10.1016/j.biopha.2023.114228. Epub 2023 Jan 7. Biomed Pharmacother. 2023. PMID: 36623448 Free article.
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.
Ferdinandy P, Andreadou I, Baxter GF, Bøtker HE, Davidson SM, Dobrev D, Gersh BJ, Heusch G, Lecour S, Ruiz-Meana M, Zuurbier CJ, Hausenloy DJ, Schulz R. Ferdinandy P, et al. Among authors: zuurbier cj. Pharmacol Rev. 2023 Jan;75(1):159-216. doi: 10.1124/pharmrev.121.000348. Epub 2022 Dec 8. Pharmacol Rev. 2023. PMID: 36753049 Free PMC article. Review.
Disruption of hexokinase II-mitochondrial binding blocks ischemic preconditioning and causes rapid cardiac necrosis.
Smeele KM, Southworth R, Wu R, Xie C, Nederlof R, Warley A, Nelson JK, van Horssen P, van den Wijngaard JP, Heikkinen S, Laakso M, Koeman A, Siebes M, Eerbeek O, Akar FG, Ardehali H, Hollmann MW, Zuurbier CJ. Smeele KM, et al. Among authors: zuurbier cj. Circ Res. 2011 May 13;108(10):1165-9. doi: 10.1161/CIRCRESAHA.111.244962. Epub 2011 Apr 28. Circ Res. 2011. PMID: 21527739
Reduced hexokinase II impairs muscle function 2 wk after ischemia-reperfusion through increased cell necrosis and fibrosis.
Smeele KM, Eerbeek O, Schaart G, Koeman A, Bezemer R, Nelson JK, Ince C, Nederlof R, Boek M, Laakso M, de Haan A, Drost MR, Hollmann MW, Zuurbier CJ. Smeele KM, et al. Among authors: zuurbier cj. J Appl Physiol (1985). 2012 Aug 15;113(4):608-18. doi: 10.1152/japplphysiol.01494.2011. Epub 2012 Jun 21. J Appl Physiol (1985). 2012. PMID: 22723631 Free article.
121 results